Everything below concerns ghrelin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Aqueous buffers also used |
| Typical dry storage | -20 °C, desiccated, dark | Low moisture slows degradation |
| Identity method | Reversed-phase HPLC with mass detection | Retention time plus mass confirmation |
| Solution stability | Shorter than the dry solid | Cold storage, avoid freeze-thaw cycling |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
These multidisciplinary teams leverage the Barshop Institute's nationally recognized aging research programs—including the Nathan Shock Center of Excellence in the Basic Biology of Aging, the Claude D. Pepper Older Americans Independence Center, the Center for Alzheimer's Disease and Related Dementias Population Aging and Social Studies (CAPAS), and the Interventions Testing Program—to rapidly translate mechanistic discoveries into human studies. This integrated research environment enables investigators to evaluate interventions targeting the fundamental biological mechanisms of aging rather than focusing solely on individual diseases, reflecting the principles of geroscience that underpin the Institute's research mission. A landmark addition to the Institute's clinical research portfolio is the Validation and Intervention Testing for Aging, Longevity and Healthspan (VITAL-H) clinical trial, supported by a contract of up to $38 million from the Advanced Research Projects Agency for Health (ARPA-H) through its Proactive Solutions for Prolonging Resilience (PROSPR) program. As the coordinating center for this first-of-its-kind national healthspan clinical trial, the Barshop Institute is leading an unprecedented effort to determine whether FDA-approved medications can slow the biological processes of aging and preserve health and functional capacity before the onset of chronic disease.
2019: New Zealand chemist Margaret Brimble is the first New Zealand woman to be inducted into the Division of Medicinal Chemistry of the American Chemical Society’s Hall of Fame. 2019: Malawian nurse and educator Address Malata is appointed as Vice-Chancellor of the Malawi University of Science and Technology (MUST), becoming the first Malawian women university Vice-Chancellor. 2019: American imaging scientist Katie Bouman developed an algorithm that made the first visualization of a black hole possible using the Event Horizon Telescope. She was part of the team of over 200 people who implemented the project.
Analogues of 4-HO-NiPT include 4-hydroxytryptamine (4-HT or 4-HO-T), 4-HO-MiPT (miprocin), 4-HO-DiPT (diprocin), psilocin (4-HO-DMT), norpsilocin (4-HO-NMT), 4-HO-NET, 4-HO-NPT, 4-HO-NALT, and 4-HO-NBnT, among others.
Sources: en.wikipedia.org
Xi's administration enacted a number of changes to the structure of the CCP and state bodies, especially in a large overhaul in 2018. These reforms have been characterized by the integration of CCP and state bodies. Beginning in 2013, the CCP under Xi has created a series of Central Leading Groups: supra-ministerial steering committees, designed to bypass existing institutions when making decisions, and ostensibly make policy-making a more efficient process. Xi was also believed to have diluted the authority of premier Li Keqiang, taking authority over the economy which has generally been considered to be the domain of the premier. February 2014 oversaw the creation of the Central Leading Group for Cybersecurity and Informatization with Xi as its leader. The State Internet Information Office (SIIO), previously under the State Council Information Office (SCIO), was transferred to the central leading group and renamed in English into the Cyberspace Administration of China. As part of managing the financial system, the Financial Stability and Development Committee, a State Council body, was established in 2017. Chaired by vice premier Liu He during its existence, the committee was disestablished by the newly established Central Financial Commission during the 2023 Party and state reforms. Xi has increased the role of the Central Financial and Economic Affairs Commission at the expense of the State Council. 2018 has seen the deepening the reform of the Party and state institutions.
=== Detection === A procedure of retrospective detection of Novichok type poisons in victim's tissues was proposed in 2021-2. This method is a modification of the procedure that was developed earlier for identification of sarin poisoning. This method capitalizes on the fact that poisoning by organic phosphonates occurs via phosphonylation of the hydroxy group of serine in the active site of cholinesterases, and that severe poisoning occurs when a major part of these enzymes are inactivated. The concentration of butyryl cholinesterase (HuBuChE) in human plasma is normally about 80 nM. That makes it a good source of adducts that can be subjected to analysis. The procedure consists of three steps (see the Figure A). First, HuBuChE is obtained from the victim's plasma. Second, the enzyme is subjected to pepsin proteolysis. Third, the peptide mixture obtained is subjected to LC-MSMS analysis. If no poisoning took place, the peptide mixture contains a non-modified nonapeptide FGESAGAAS. However, cholinesterases are inactivated due to a chemical reaction with Novichok type nerve agent, the modified nonapeptide is be detected, and its exact (high resolution) mass (along with the mass of the secondary ion produced during collision induced dissociation) allows unambiguous identification of the fact of poisoning and the exact structure of the poison. Thus, the example at Figure A shows the masses of the primary and secondary ions obtained from the plasma of the victim poisoned by A-230. If a victim is poisoned by other Novichok type agents, the masses are different.
White House National Security Advisor Jake Sullivan responded to the report saying there was still "no definitive answer" to the question of the pandemic's origins. On 28 February 2023, the head of the Federal Bureau of Investigation (FBI), Christopher Wray, said the bureau believes Covid-19 most likely originated in the lab. The FBI concluded with "moderate confidence" that COVID-19 may have been created in a laboratory, based in part on genomic analysis conducted by scientists at the National Center for Medical Intelligence. On 20 March 2023, the COVID-19 Origin Act of 2023 was signed into law. On 23 June 2023, the Biden administration released its report, as required by the Act.
A writer for Business Insider called it one of the best performances of DiCaprio's career, and Ian Sandwell of Digital Spy particularly liked the duo's chemistry, believing their scenes together to be some of the film's strongest parts. DiCaprio received nominations for an Oscar, a Golden Globe, a BAFTA Award and a Screen Actors Guild Award for Best Actor. The film earned $374 million against a budget of $90 million. In 2020, DiCaprio served as an executive producer for The Right Stuff, a television series adaption of the 1973 namesake book. After being in development at National Geographic, it was released on Disney+. That May, DiCaprio briefly featured in the finale of the miniseries The Last Dance. In 2021, DiCaprio appeared in Adam McKay's satirical comedy Don't Look Up. He spent five months changing the film's script with McKay before agreeing to the part. Starring alongside Jennifer Lawrence as two astronomers attempting to warn humanity about an extinction-level comet, DiCaprio saw this film as an analogy of the world's indifference to the climate crisis. As a frequent supporter of environmentalism, DiCaprio said he has often looked to star in and make films tackling issues related to it, something he found hard due to people's inability to listen. He praised McKay for envisioning a project on how humans would react to a serious issue from a political, social and scientific standpoint. While reviews for the film were mixed, most critics praised DiCaprio's and Lawrence's performances; journalists from Digital Spy and NDTV lauded their pairing.
Sources: en.wikipedia.org
== B == Baeyer–Drewsen indigo synthesis (also commonly incorrectly named Baeyer–Drewson indigo synthesis) Baeyer–Villiger oxidation, Baeyer–Villiger rearrangement Bakeland process (Bakelite) Baker–Venkataraman rearrangement, Baker–Venkataraman transformation Baldwin's rules Bally–Scholl synthesis Balz–Schiemann reaction Bamberger rearrangement Bamberger triazine synthesis Bamford–Stevens reaction Barbier reaction Barbier–Wieland degradation Bardhan–Sengupta phenanthrene synthesis Barfoed's test Bargellini reaction Bartoli indole synthesis, Bartoli reaction Barton decarboxylation Barton reaction Barton–Kellogg reaction Barton–McCombie reaction, Barton deoxygenation Barton-Zard Synthesis Barton vinyl iodine procedure Baudisch reaction Bayer test Baylis–Hillman reaction Bechamp reaction Bechamp reduction Beckmann fragmentation Beckmann rearrangement Bellus–Claisen rearrangement Belousov–Zhabotinsky reaction Benary reaction Benedict's reagent Benkeser reaction Benzidine rearrangement Benzilic acid rearrangement Benzoin condensation Bergman cyclization Bergmann azlactone peptide synthesis Bergmann degradation Bergmann–Zervas carbobenzoxy method Bernthsen acridine synthesis Bestmann's reagent Betti reaction Biginelli pyrimidine synthesis Biginelli reaction Bingel reaction Birch reduction Bischler–Möhlau indole synthesis Bischler–Napieralski reaction Biuret test Blaise ketone synthesis Blaise reaction Blanc reaction Blanc chloromethylation Blum–Ittah aziridine synthesis Bodroux reaction Bodroux–Chichibabin aldehyde synthesis Bogert–Cook synthesis Bohlmann-Rahtz pyridine synthesis Bohn–Schmidt reaction Boord olefin synthesis Borodin reaction Borsche–Drechsel cyclization Bosch–Meiser urea process Bosch reaction Bouveault aldehyde synthesis Bouveault–Blanc reduction Boyland–Sims oxidation Boyer Reaction Bredt's rule Brook rearrangement Brown hydroboration Bucherer carbazole synthesis Bucherer reaction Bucherer–Bergs reaction Buchner ring enlargement Büchner–Curtius–Schlotterbeck reaction Buchwald–Hartwig amination Bunnett reaction Burgess reagent
Collagen alpha-3(V) chain is a protein that in humans is encoded by the COL5A3 gene. This gene encodes an alpha chain for one of the low abundance fibrillar collagens. Fibrillar collagen molecules are trimers that can be composed of one or more types of alpha chains. Type V collagen is found in tissues containing type I collagen and appears to regulate the assembly of heterotypic fibers composed of both type I and type V collagen. This gene product is closely related to type XI collagen and it is possible that the collagen chains of types V and XI constitute a single collagen type with tissue-specific chain combinations. Mutations in this gene are thought to be responsible for the symptoms of a subset of patients with Ehlers–Danlos syndrome type III. Messages of several sizes can be detected in northern blots but sequence information cannot confirm the identity of the shorter messages.
==== Platelet-type ==== Platelet-type VWD (also known as pseudo-VWD) is an autosomal dominant genetic defect of the platelets. The VWF is qualitatively normal and genetic testing of the von Willebrand gene and VWF protein reveals no mutational alteration. The defect lies in the qualitatively altered GPIb receptor on the platelet membrane which increases its affinity to bind to the VWF. Large platelet aggregates and high molecular weight VWF multimers are removed from the circulation resulting in thrombocytopenia and diminished or absent large VWF multimers. The ristocetin cofactor activity and loss of large VWF multimers are similar to VWD type 2B.
Sources: en.wikipedia.org
Typical guidance is -20 °C in a sealed container with desiccant and protection from light. The powder tolerates handling better than a solution, but repeated warming and cooling is still avoided.
Chromatography separates components by retention behavior, while mass spectrometry reports molecular mass and fragment patterns. Together they confirm identity and reveal modifications that a single retention time could miss.
Immunoassays are useful for estimating concentrations in biological samples but depend on antibody specificity. Related secretagogues or fragments may bind the same antibody, so cross-reactivity limits their use for definitive identity confirmation.
Dry powder is typically kept frozen, desiccated, and protected from light. Avoiding moisture exposure and large temperature swings helps slow degradation. Storage recommendations vary by supplier and should be followed for the specific material.